Biodesix to participate at Morgan Stanley 20th Annual Global Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference
Rewatch the live fireside chat during Canaccord Genuity 42nd Annual Growth Conference, featuring Scott Hutton, CEO of Biodesix Inc.
Biodesix is recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022.
Biodesix, Inc. (Nasdaq: BDSX) announced its financial and operating results for second quarter ended June 30, 2022 and provided a corporate update.
Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.
Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors
Biodesix announced today that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4
Adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment
The Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, provides coverage for the Nodify CDT® lung nodule test.
Aim is to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad, Inc.